Aptose Biosciences APTO Stock
Aptose Biosciences Price Chart
Aptose Biosciences APTO Financial and Trading Overview
| Aptose Biosciences stock price | 1.25 USD |
| Previous Close | 5.97 USD |
| Open | 5.97 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 900 |
| Day's Range | 5.75 - 6 USD |
| 52 Week Range | 0.36 - 6.6 USD |
| Volume | 42.93K USD |
| Avg. Volume | 236K USD |
| Market Cap | 37.14M USD |
| Beta (5Y Monthly) | 1.677149 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.83 USD |
APTO Valuation Measures
| Enterprise Value | 486.22M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.85362315 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 21.111109 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -10.785 |
Trading Information
Aptose Biosciences Stock Price History
| Beta (5Y Monthly) | 1.677149 |
| 52-Week Change | 609.63% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.6 USD |
| 52 Week Low | 0.36 USD |
| 50-Day Moving Average | 1.36 USD |
| 200-Day Moving Average | 0.81 USD |
APTO Share Statistics
| Avg. Volume (3 month) | 236K USD |
| Avg. Daily Volume (10-Days) | 203.41K USD |
| Shares Outstanding | 6.26M |
| Float | 81.09M |
| Short Ratio | 1.53 |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | 30.9K |
| Short % of Float | 0.50% |
| Short % of Shares Outstanding | 0.48% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -50.47% |
| Return on Equity (ttm) | -96.44% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -45082000 USD |
| Net Income Avi to Common (ttm) | -44018000 USD |
| Diluted EPS (ttm) | -6.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 35.72M USD |
| Total Cash Per Share (mrq) | 0.38 USD |
| Total Debt (mrq) | 1.22M USD |
| Total Debt/Equity (mrq) | 4.71 USD |
| Current Ratio (mrq) | 3.054 |
| Book Value Per Share (mrq) | 0.279 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33979000 USD |
| Levered Free Cash Flow (ttm) | -17715750 USD |
Profile of Aptose Biosciences
| Country | United States |
| State | ON |
| City | Toronto |
| Address | 251 Consumers Road |
| ZIP | M2J 4R3 |
| Phone | 647-479-9828 |
| Website | https://www.aptose.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 35 |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Q&A For Aptose Biosciences Stock
What is a current APTO stock price?
Aptose Biosciences APTO stock price today per share is 1.25 USD.
How to purchase Aptose Biosciences stock?
You can buy APTO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aptose Biosciences?
The stock symbol or ticker of Aptose Biosciences is APTO.
Which industry does the Aptose Biosciences company belong to?
The Aptose Biosciences industry is Biotechnology.
How many shares does Aptose Biosciences have in circulation?
The max supply of Aptose Biosciences shares is 17.45M.
What is Aptose Biosciences Price to Earnings Ratio (PE Ratio)?
Aptose Biosciences PE Ratio is now.
What was Aptose Biosciences earnings per share over the trailing 12 months (TTM)?
Aptose Biosciences EPS is -7.58 USD over the trailing 12 months.
Which sector does the Aptose Biosciences company belong to?
The Aptose Biosciences sector is Healthcare.
Aptose Biosciences APTO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}